Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,036 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL, Idorn T, Lawson J, Mahaffey KW, Mann JFE, Mersebach H, Perkovic V, Tuttle K, Pratley R. Rossing P, et al. Among authors: bakris g. Nephrol Dial Transplant. 2023 Aug 31;38(9):2041-2051. doi: 10.1093/ndt/gfad009. Nephrol Dial Transplant. 2023. PMID: 36651820 Free PMC article. Clinical Trial.
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
Bakris GL, Ruilope LM, Anker SD, Filippatos G, Pitt B, Rossing P, Fried L, Roy-Chaudhury P, Sarafidis P, Ahlers C, Brinker M, Joseph A, Lawatscheck R, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Bakris GL, et al. Kidney Int. 2023 Jan;103(1):196-206. doi: 10.1016/j.kint.2022.08.040. Epub 2022 Oct 28. Kidney Int. 2023. PMID: 36367466 Free article.
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, Filippatos G, Pitt B, Rossing P, Lambelet M, Nowack C, Kolkhof P, Joseph A, Bakris GL. Agarwal R, et al. Among authors: bakris gl. J Hypertens. 2023 Feb 1;41(2):295-302. doi: 10.1097/HJH.0000000000003330. Epub 2022 Dec 8. J Hypertens. 2023. PMID: 36583355 Free PMC article. Clinical Trial.
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, Małyszko J, Ruilope LM, Rossignol P, Rossing P, Pecoits-Filho R, Anker SD, Joseph A, Lawatscheck R, Wilson D, Gebel M, Bakris GL. Agarwal R, et al. Among authors: bakris gl. Clin Kidney J. 2022 Oct 30;16(2):293-302. doi: 10.1093/ckj/sfac234. eCollection 2023 Feb. Clin Kidney J. 2022. PMID: 36864892 Free PMC article.
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, Pollock C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Neal B, Wheeler DC, Cannon CP, Zhang H, Zinman B, Perkovic V, Levin A, Mahaffey KW, Jardine M; CREDENCE Trial Investigators. Yi TW, et al. Among authors: bakris g. Am J Kidney Dis. 2023 Jul;82(1):84-96.e1. doi: 10.1053/j.ajkd.2022.12.015. Epub 2023 Mar 7. Am J Kidney Dis. 2023. PMID: 36889425 Clinical Trial.
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.
Charytan DM, Mahaffey KW, Jardine MJ, Cannon CP, Neal B, Lambers Heerspink HJ, Agarwal R, Bakris GL, de Zeeuw D, Levin A, Pollock C, Zhang H, Zinman B, Rosenthal N, Perkovic V, Di Tanna GL, Yu J, Rogers K, Arnott C, Wheeler DC. Charytan DM, et al. BMJ Open Diabetes Res Care. 2023 Jun;11(3):e003270. doi: 10.1136/bmjdrc-2022-003270. BMJ Open Diabetes Res Care. 2023. PMID: 37311602 Free PMC article. Clinical Trial.
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
Agarwal R, Pitt B, Rossing P, Anker SD, Filippatos G, Ruilope LM, Kovesdy CP, Tuttle K, Vaduganathan M, Wanner C, Bansilal S, Gebel M, Joseph A, Lawatscheck R, Bakris GL. Agarwal R, et al. Among authors: bakris gl. JAMA Cardiol. 2023 Aug 1;8(8):732-741. doi: 10.1001/jamacardio.2023.1505. JAMA Cardiol. 2023. PMID: 37314801 Free PMC article.
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.
Heerspink HJL, Vart P, Jongs N, Neuen BL, Bakris G, Claggett B, Vaduganathan M, McCausland F, Docherty KF, Jhund PS, Solomon SD, Perkovic V, McMurray JJV. Heerspink HJL, et al. Among authors: bakris g. Diabetes Obes Metab. 2023 Nov;25(11):3327-3336. doi: 10.1111/dom.15232. Epub 2023 Aug 14. Diabetes Obes Metab. 2023. PMID: 37580309 Free article.
1,036 results